Clinical Trials Logo

Filter by:
NCT ID: NCT05027087 Completed - Dry Eye Clinical Trials

The Effect of a Novel Blueberry Supplement on Dry Eye Disease

PLUM
Start date: September 9, 2021
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the efficacy of a novel oral supplement (gummy bear) with blueberry powder on reducing dry eye signs and symptoms and assess its safety.

NCT ID: NCT05027074 Active, not recruiting - Clinical trials for Kidney Failure, Chronic

Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)

Start date: September 17, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of two different doses of MK-2060 (a monoclonal antibody against Factor XI) in end stage renal disease (ESRD) participants receiving hemodialysis via an arteriovenous graft (AVG). Data from this study will be used to aid dose selection of MK-2060 in future studies. The primary hypothesis is that at least one of the MK-2060 doses is superior to placebo in increasing the time to first occurrence of AVG event.

NCT ID: NCT05026645 Enrolling by invitation - Clinical trials for Acute Respiratory Distress Syndrome

The Medical Management in Patients Exposed to Weapons of Mass Destruction

CBRNEObs
Start date: October 1, 2020
Phase:
Study type: Observational

Observation study measuring medical response in contaminated environment.

NCT ID: NCT05026554 Recruiting - Atopic Dermatitis Clinical Trials

Characterization of Chronic Hand Eczema

Start date: June 30, 2021
Phase:
Study type: Observational

Prospective longitudinal study to characterize Choronic Hand Eczema (CHE) subtypes and Atopic Dermatitis (AD) with noninvasive molecular and imaging techniques, and assess changes through time and its association with quality of life.

NCT ID: NCT05026385 Completed - Obesity Clinical Trials

The POMELO (Prevention Of MusclE Loss in Osteoarthritis) Trial

POMELO
Start date: September 20, 2021
Phase: N/A
Study type: Interventional

Treatment options for individuals who have advanced knee osteoarthritis (OA) and a body mass index (BMI) ≥35 kg/m2 are limited, and this patient population may be neglected in current clinical care pathways for OA management. These individuals are considered to be at high risk for complications with total knee arthroplasty (TKA), and as a result may not be eligible for this procedure unless they lose significant weight. However, there is limited evidence for endorsing weight loss as beneficial prior to TKA. Further, unsupervised weight loss could put patients at risk for muscle loss and development of sarcopenic obesity, a health condition that negatively impacts mobility and mortality. This suggests that weight loss might not be the primary treatment goal for this patient population. Integrated non-surgical treatment approaches are needed that can target the specific needs of this knee OA patient group. This study will examine the feasibility and acceptability of a personalized, multicomponent intervention, and its effects on body composition and physical function compared to usual care.

NCT ID: NCT05026177 Active, not recruiting - Alzheimer Disease Clinical Trials

Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

REFOCUS-ALZ
Start date: November 18, 2021
Phase: Phase 3
Study type: Interventional

A 76-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 76 weeks. Approximately 1083 participants will be randomized (1:1:1) to receive either placebo, 50 mg tablets of simufilam, or 100 mg tablets of simufilam, twice daily, for 76 weeks. Clinic visits will occur 4 weeks after the baseline visit, and then every 12 weeks until the end of the study. The safety of simufilam, and its efficacy in enhancing cognition and slowing cognitive and functional decline will be evaluated.

NCT ID: NCT05025878 Recruiting - Ovarian Cancer Clinical Trials

13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.

iMETABO
Start date: October 20, 2021
Phase:
Study type: Observational

The objective of the study is to investigate the metabolism of cells in the ascites tumour microenvironment of ovarian cancer patients. This observational study involves intravenous infusion of [U-13C]glucose into patients during standard paracentesis.

NCT ID: NCT05025852 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

The Effect of In-utero Exposure to Metformin in 5-11 Year Old Offspring of Mothers in the MiTy Trial

MiTy Tykes
Start date: May 11, 2022
Phase:
Study type: Observational

The incidence of diabetes in pregnancy is rising, with rates of 1 in 7 pregnancies globally. Metformin is used for type 2 diabetes (T2DM) outside of pregnancy and is now increasingly prescribed during pregnancy. There are some concerns as metformin crosses the placenta and effects on offspring exposed during pregnancy are unknown. Animal and human evidence indicate that metformin may create an atypical in-utero environment similar to under-nutrition which has been associated with adult obesity. This is supported by studies in children of mothers treated with metformin in other populations where an increase in childhood obesity was found at 4-9 years of age. We now have evidence from the MiTy trial, that offspring of metformin-exposed women with T2DM have less large infants and are less adipose at birth, but are also more likely to be small for gestational age (SGA). These effects could lead to benefit or harm in the long-term. Offspring of MiTy mothers are currently being followed up to 2 years. Given that long-term effects may not be evident until 5 years of age, it is imperative to follow these children longer. Goals/Research Aims:To determine whether in-utero exposure to metformin, in offspring of women with T2DM, is beneficial or harmful in the long-term. Research Questions: 1. In offspring of women with T2DM, how does treatment with metformin during pregnancy affect a) adiposity b) growth over time c) metabolic syndrome d) cognitive and behavioral measures:2. What factors predict altered childhood adiposity and insulin resistance in these offspring? Primary Outcome: Body mass index (BMI) z-score. Secondary Outcomes: 1) other measures of adiposity (i.e. skinfolds, 2) growth over time 3) measures of insulin resistance 4) adipocytokines 5)neurodevelopment Expected Outcomes Given these increasing concerns, this study will inform the best treatment for pregnant mothers with diabetes by studying the long-term outcomes of children exposed to metformin during pregnancy.

NCT ID: NCT05025462 Active, not recruiting - Metabolic Syndrome Clinical Trials

Salmon Peptide Fraction: Safety and Cardiometabolic Health

SPF1
Start date: November 1, 2021
Phase: N/A
Study type: Interventional

The overall goal of this study is to verify the safety of 15g of salmon peptide fraction (SPF), and to test the effects on metabolic syndrome risk factors of two doses of SPF (7.5g and 15g) in overweight-obese men and women. Transcriptomic, metabolomic and metagenomic approaches will be used to study the physiological effects of SPF and to discover the potential mechanism underlying these effects.

NCT ID: NCT05025254 Recruiting - Parkinson Disease Clinical Trials

Cognitive Testing Online in Parkinson's Disease

Start date: August 2021
Phase:
Study type: Observational

This is a feasibility and pilot study. Though large-scale online neurocognitive testing is increasingly being done in psychiatry, there are no such efforts in Parkinson's research. Thus a large part of this pilot study will be to demonstrate feasibility and reliability, and use this experience to develop a feasible protocol for ongoing research. The specific short-term objectives are: 1. To establish the feasibility of performing large-scale deep cognitive phenotyping using online cognitive testing. 2. To demonstrate that online neurocognitive testing is valid and reliable in a smaller sample of locally recruited participants tested both in-lab and online.